Skip to main content
Erschienen in: Clinical Pharmacokinetics 4/2003

01.04.2003 | Leading Article

Pharmacokinetic Principles of Bacteriophage Therapy

verfasst von: Dr Robert J. H. Payne, Vincent A. A. Jansen

Erschienen in: Clinical Pharmacokinetics | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Use of bacteriophage to control bacterial infections, including antibioticresistant infections, shows increasing therapeutic promise. Effective bacteriophage therapy requires awareness of various novel kinetic phenomena not known in conventional drug treatments. Kinetic theory predicts that timing of treatment could be critical, with the strange possibility that inoculations given too early could be less effective or fail completely. Another paradoxical result is that adjuvant use of an antibiotic can sometimes diminish the efficacy of phage therapy. For a simple kinetic model, mathematical formulae predict the values of critical density thresholds and critical time points, given as functions of independently measurable biological parameters. Understanding such formulae is important for interpreting data and guiding experimental design. Tailoring pharmacokinetic models for specific systems needs to become standard practice in future studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sharp R. Bacteriophages: biology and history. J Chem Tech Biotechnol 2001; 76: 667–72CrossRef Sharp R. Bacteriophages: biology and history. J Chem Tech Biotechnol 2001; 76: 667–72CrossRef
2.
Zurück zum Zitat d’Herelle F. Sur un microbe invisible antagoniste des bacilles dysenteriques. C R Acad Sci 1917; 165: 373–5 d’Herelle F. Sur un microbe invisible antagoniste des bacilles dysenteriques. C R Acad Sci 1917; 165: 373–5
3.
Zurück zum Zitat Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649–59PubMedCrossRef Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649–59PubMedCrossRef
5.
Zurück zum Zitat Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996; 275: 300–4PubMedCrossRef Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996; 275: 300–4PubMedCrossRef
7.
Zurück zum Zitat Payne RJH, Jansen VAA. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 2000; 68: 225–9PubMedCrossRef Payne RJH, Jansen VAA. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 2000; 68: 225–9PubMedCrossRef
8.
Zurück zum Zitat Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 2001; 208: 37–48PubMedCrossRef Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 2001; 208: 37–48PubMedCrossRef
9.
Zurück zum Zitat Alisky J, Iczkowski K, Rapoport A, et al. Bacteriophage show promise as antimicrobial agents. J Infect 1998; 36: 5–15PubMedCrossRef Alisky J, Iczkowski K, Rapoport A, et al. Bacteriophage show promise as antimicrobial agents. J Infect 1998; 36: 5–15PubMedCrossRef
10.
Zurück zum Zitat Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997; 5: 268–71PubMedCrossRef Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997; 5: 268–71PubMedCrossRef
11.
Zurück zum Zitat Barrow PA. The use of bacteriophages for treatment of bacterial disease in animals and animal models of human infection. J Chem Tech Biotechnol 2001; 76: 677–82CrossRef Barrow PA. The use of bacteriophages for treatment of bacterial disease in animals and animal models of human infection. J Chem Tech Biotechnol 2001; 76: 677–82CrossRef
12.
Zurück zum Zitat Chanishvili N, Chanishvili T, Tediashvili M, et al. Phages and their application against drug-resistant bacteria. J Chem Tech Biotechnol 2001; 76: 689–99CrossRef Chanishvili N, Chanishvili T, Tediashvili M, et al. Phages and their application against drug-resistant bacteria. J Chem Tech Biotechnol 2001; 76: 689–99CrossRef
14.
Zurück zum Zitat Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569–83 Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569–83
15.
Zurück zum Zitat Cislo M, Dabrowski M, Slopek S. Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987; 35: 175–83 Cislo M, Dabrowski M, Slopek S. Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987; 35: 175–83
16.
Zurück zum Zitat Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 563–8 Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 563–8
17.
Zurück zum Zitat Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 553–61 Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 553–61
18.
Zurück zum Zitat Abdul-Hassan HS, El-Tahan E, Massoud B, et al. Bacterio-phage therapy of Pseudomonas burn wound sepsis. Ann Medit Burn Club 1990; 3: 262–4 Abdul-Hassan HS, El-Tahan E, Massoud B, et al. Bacterio-phage therapy of Pseudomonas burn wound sepsis. Ann Medit Burn Club 1990; 3: 262–4
19.
Zurück zum Zitat Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129: 2659–75PubMed Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129: 2659–75PubMed
20.
Zurück zum Zitat Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987; 133: 1111–26PubMed Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987; 133: 1111–26PubMed
21.
Zurück zum Zitat Berchieri A, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res Microbiol 1991; 142: 541–9PubMedCrossRef Berchieri A, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res Microbiol 1991; 142: 541–9PubMedCrossRef
22.
Zurück zum Zitat Soothill JS. Treatment of experimental infection of mice with bacteriophages. J Med Microbiol 1992; 37: 258–61PubMedCrossRef Soothill JS. Treatment of experimental infection of mice with bacteriophages. J Med Microbiol 1992; 37: 258–61PubMedCrossRef
23.
Zurück zum Zitat Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209–11PubMedCrossRef Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209–11PubMedCrossRef
24.
Zurück zum Zitat Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chicken and calves. Clin Diag Lab Immun 1998; 5: 294–8 Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chicken and calves. Clin Diag Lab Immun 1998; 5: 294–8
25.
Zurück zum Zitat Ramesh V, Fralick JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 1999; 5: 69–78CrossRef Ramesh V, Fralick JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 1999; 5: 69–78CrossRef
26.
Zurück zum Zitat Nakai T, Sugimoto R, Park KH, et al. Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail. Dis Aquat Organ 1999; 37: 33–41PubMedCrossRef Nakai T, Sugimoto R, Park KH, et al. Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail. Dis Aquat Organ 1999; 37: 33–41PubMedCrossRef
27.
Zurück zum Zitat Park SC, Shimamura I, Fukunaga M, et al. Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 2000; 66: 1416–22PubMedCrossRef Park SC, Shimamura I, Fukunaga M, et al. Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 2000; 66: 1416–22PubMedCrossRef
28.
Zurück zum Zitat Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307–18PubMed Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307–18PubMed
29.
Zurück zum Zitat Cao J, Sun Y-Q, Berglindh T, et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim Biophys Acta 2000; 1474: 107–13PubMedCrossRef Cao J, Sun Y-Q, Berglindh T, et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim Biophys Acta 2000; 1474: 107–13PubMedCrossRef
30.
Zurück zum Zitat Gotelli NJ. A primer of ecology. Sunderland (MA): Sinauer, 1998 Gotelli NJ. A primer of ecology. Sunderland (MA): Sinauer, 1998
31.
Zurück zum Zitat Anderson RM, May RM. Infectious diseases of humans. Oxford (UK): Oxford University Press, 1992 Anderson RM, May RM. Infectious diseases of humans. Oxford (UK): Oxford University Press, 1992
32.
Zurück zum Zitat Campbell A. Conditions for the existence of bacteriophage. Evolution 1961; 15: 153–65CrossRef Campbell A. Conditions for the existence of bacteriophage. Evolution 1961; 15: 153–65CrossRef
33.
Zurück zum Zitat Levin BR, Stewart FM, Chao L. Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am Nat 1977; 111: 3–24CrossRef Levin BR, Stewart FM, Chao L. Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am Nat 1977; 111: 3–24CrossRef
34.
Zurück zum Zitat Schrag SJ, Mittler JE. Host-parasite coexistence: the role of spatial refuges in stabilizing bacteria-phage interactions. Am Nat 1996; 148: 348–77CrossRef Schrag SJ, Mittler JE. Host-parasite coexistence: the role of spatial refuges in stabilizing bacteria-phage interactions. Am Nat 1996; 148: 348–77CrossRef
35.
Zurück zum Zitat Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2: 187–99PubMed Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2: 187–99PubMed
36.
Zurück zum Zitat Slopek S, Durlakowa I, Weber-Dabrowska B, et al. Results of bacteriophage treatment of suppurative bacterial infections I: general evaluation of the results. Arch Immunol Ther Exp (Warsz) 1983; 31: 267–91 Slopek S, Durlakowa I, Weber-Dabrowska B, et al. Results of bacteriophage treatment of suppurative bacterial infections I: general evaluation of the results. Arch Immunol Ther Exp (Warsz) 1983; 31: 267–91
37.
Zurück zum Zitat Sakandelidze VM. Kompleksnoe primenie spetsificheskikh fagov i antibiotikov pri razlichnykh infektsionnykh allergozakh. [The combined use of specific phages and antibiotics in different infectious allergoses] [in Russian]. Vrach Delo 1991; 3: 60–3PubMed Sakandelidze VM. Kompleksnoe primenie spetsificheskikh fagov i antibiotikov pri razlichnykh infektsionnykh allergozakh. [The combined use of specific phages and antibiotics in different infectious allergoses] [in Russian]. Vrach Delo 1991; 3: 60–3PubMed
38.
Zurück zum Zitat Levin BR, Bull JJ. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 1996; 147: 881–98CrossRef Levin BR, Bull JJ. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 1996; 147: 881–98CrossRef
39.
Zurück zum Zitat Bull JJ, Levin BR, DeRouin T, et al. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2002 Nov 26; 2(1): 35PubMedCrossRef Bull JJ, Levin BR, DeRouin T, et al. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2002 Nov 26; 2(1): 35PubMedCrossRef
40.
Zurück zum Zitat Hawkins BA, Cornell HV, editors. Theoretical approaches to biological control. Cambridge (UK): Cambridge University Press, 1999 Hawkins BA, Cornell HV, editors. Theoretical approaches to biological control. Cambridge (UK): Cambridge University Press, 1999
Metadaten
Titel
Pharmacokinetic Principles of Bacteriophage Therapy
verfasst von
Dr Robert J. H. Payne
Vincent A. A. Jansen
Publikationsdatum
01.04.2003
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 4/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342040-00002

Weitere Artikel der Ausgabe 4/2003

Clinical Pharmacokinetics 4/2003 Zur Ausgabe